Fundraisings and IPOs

Date: 2017-09-18

Type of information: Grant

Company: Soligenix (USA - NJ)

Investors: National Cancer Institute (NCI) (USA)

Amount: $1.5 million

Funding type: grant

Planned used: The Small Business Innovation Research (SBIR) grant of approximately $1.5 million over two years will be used to support the conduct of Soligenix's pivotal, Phase 3, randomized, double-blind, placebo-controlled study evaluating SGX301 (synthetic hypericin) as a treatment for cutaneous T-cell lymphoma.

Others:

• • On September 18, 2017, Soligenix announced that the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), has awarded a Small Business Innovation Research (SBIR) grant of approximately $1.5 million over two years to support the conduct of its pivotal, Phase 3, randomized, double-blind, placebo-controlled study evaluating SGX301 (synthetic hypericin) as a treatment for cutaneous T-cell lymphoma.

Therapeutic area: Cancer - Oncology

Is general: Yes